Roche Holding | ROG - Cost Of Sales


Roche Holding reported CHF8.48B in Cost of Sales for its fiscal semester ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alcon AG USD 1.2B 46M Dec/2025
Almirall EUR 191.5M 2.29M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bayer EUR 4.5B 194M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Fresenius EUR 4.45B 262M Dec/2025
Fresenius Medical Care EUR 3.68B 38.37M Dec/2025
Galapagos EUR 455K 84.28M Dec/2025
Genmab DKK 81M 23M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
GRIFOLS EUR 1.29B 163.12M Dec/2025
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.29B 183M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Orion EUR 163.7M 22.9M Mar/2026
Pfizer USD 6.29B 2.12B Dec/2025
Philips EUR 2.81B 417M Dec/2025
Recordati EUR 199.91M 20.12M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025